Premium
In vitro evaluation of antimicrobial activity of L actobacillus rhamnosus IMC 501 ® , L actobacillus paracasei IMC 502 ® and SYNBIO ® against pathogens
Author(s) -
Coman M.M.,
Verdenelli M.C.,
Cecchini C.,
Silvi S.,
Orpianesi C.,
Boyko N.,
Cresci A.
Publication year - 2014
Publication title -
journal of applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.889
H-Index - 156
eISSN - 1365-2672
pISSN - 1364-5072
DOI - 10.1111/jam.12544
Subject(s) - lactobacillus paracasei , lactobacillus rhamnosus , probiotic , microbiology and biotechnology , antimicrobial , lactobacillus , biology , pathogen , bacteria , genetics
Aims Probiotic lactobacilli have a great potential to produce antimicrobial compounds that inhibit and control the microbial pathogen growth. The antimicrobial and antifungal activities of two probiotic strains, L actobacillus rhamnosus IMC 501 ® and L actobacillus paracasei IMC 502 ® , and their 1 : 1 combination, named SYNBIO ® , were studied using four different methods. Methods and Results Using two modified streak methods and a well diffusion method, the inhibitory activity of the probiotics and their metabolites towards six Gram‐positive, nine Gram‐negative pathogenic bacterial strains and eight C andida strains was tested. Antagonistic effect of probiotic L actobacillus strains was also investigated by coculturing assay highlighting a significant inhibition of most of the pathogens tested in this study. The combination SYNBIO ® showed a microbicidal activity against most of the strains tested in the study. Conclusions Compared with the control, most of the pathogenic bacteria and yeast were inhibited by all probiotic strains tested to various degrees. Significance and Impact of the Study Screening L actobacillus strains according to their activity in various environmental conditions could precede the clinical efficacy studies for adjunct treatment with probiotics in cure of different gastrointestinal and vaginal tract infections.